Cidara Therapeutics (CDTX) announced it gave a late-breaking presentation on its non-vaccine influenza preventative candidate, CD388, at the European Scientific Working Group on Influenza’s, ESWI, 10th Influenza Conference taking place October 20-23, 2025 in Valencia, Spain. Summary: Following lethal dosing of influenza, mice that received a single dose of CD388 demonstrated potent activity against 12 seasonal and multiple pandemic influenza subtypes, and plasma concentrations at the time of infection conferred complete protection. In Cidara’s Phase 2b study, CD388 demonstrated statistically significant prevention efficacy for all dose groups, and plasma concentration analysis at onset of infection showed that lower drug concentrations correlated with higher infection rates. Exposure response modeling revealed a clear concentration-response relationship, indicating a strong alignment between efficacious exposures in preclinical mouse influenza models and prevention efficacy observed in Cidara’s recent Phase 2b NAVIGATE trial.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Promising Phase 2b Results for Cidara’s CD388 Justify Buy Rating Amidst Strong Preventive Efficacy Against Influenza
- Cidara Therapeutics announces Phase 2b presentation on CD388 at ID Week 2025
- Cidara Therapeutics initiated with an Overweight at Morgan Stanley
- Buy Rating for Cidara Therapeutics: Promising Antiviral CD388 Targets $5 Billion Influenza Market
- Align downgraded, NetEase upgraded: Wall Street’s top analyst calls